To the Editor: Carbapenemase-producing Enterobacteriaceae are being reported worldwide.Travel, medical tourism, and cross-border transfer of patients might play a role in the spread of these bacteria (1,2).Klebsiella pneumoniae co-producing New Delhi metallo-β-lactamase 5 (NDM-5) and oxacillinase 181 (OXA-181) carbapenemases was detected in South Korea in 2014.On April 13, a 75-year-old man who had had a cerebral infarction was transferred from a tertiary care hospital in Abu Dhabi, United Arab Emirates (UAE), to Samsung Medical Center (Seoul, South Korea) for rehabilitation therapy.In Abu Dhabi, he had received broad-spectrum antimicrobial drugs for aspiration pneumonia.While at Samsung Medical Center, he experienced septic shock and acute respiratory failure due to pneumonia and was transferred to the medical intensive care unit (ICU).Carbapenem-resistant K. pneumoniae (strain CC1409-1) was isolated from a culture of bronchoalveolar lavage fluid.He was given meropenem and colistin for treatment of pneumonia, was discharged, and returned to the UAE.Four months later, carbapenem-resistant K. pneumoniae (strain CC1410-1) was identified in the tracheal aspirate of a 74-year-old woman admitted to the surgical ICU at Samsung Medical Center for traumatic intracranial hemorrhage.She had no underlying disease or previous history of hospitalization or travel abroad.She was given colistin and piperacillin/tazobactam.Following the identification of colistin resistance, colistin was switched to tigecycline.